Home › Compare › STAB vs ORCC

STAB vs ORCC: Dividend Comparison 2026

STAB yields 500000.00% · ORCC yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STAB wins by $4.663521010693878e+33M in total portfolio value
10 years
STAB
STAB
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full STAB calculator →
ORCC
ORCC
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full ORCC calculator →

Portfolio growth — STAB vs ORCC

📍 STAB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTABORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STAB + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
STAB pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STAB
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
ORCC
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, STAB beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STAB + ORCC for your $10,000?

STAB: 50%ORCC: 50%
100% ORCC50/50100% STAB
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

STAB
No analyst data
Altman Z
-22.8
Piotroski
4/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
-68.0% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STAB buys
0
ORCC buys
0
No recent congressional trades found for STAB or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTABORCC
Forward yield500000.00% ✓4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR0%5% ✓
Portfolio after 10y$4.663521010693878e+33M$28.0K ✓
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00 ✓$899.19
Total dividends collected$4.6634009849658873e+33M$6.4K ✓
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: STAB vs ORCC ($10,000, DRIP)

YearSTAB PortfolioSTAB Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,120$420.00+$50.00M → STAB
2$233,748,371,262$233,694,859,813.08$12,357$458.31+$233748.36M → STAB
3$1,021,074,511,412,696$1,020,824,400,655,446.10$13,721$499.76+$1021074511.40M → STAB
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$15,227$544.58+$4168597328794.94M → STAB
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$16,885$593.02+$15905475114600664.00M → STAB
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$18,713$645.34+$56718938532531060736.00M → STAB
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$20,724$701.81+$1.8903180743562385e+23M → STAB
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$22,938$762.73+$5.8879981047651824e+26M → STAB
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$25,372$828.41+$1.7140642681147225e+30M → STAB
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$28,047$899.19+$4.663521010693878e+33M → STAB

STAB vs ORCC: Complete Analysis 2026

STAB — Stock

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.

Full STAB Calculator →

ORCC — BDC

ORCC is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in ORCC shares.

Full ORCC Calculator →
📬

Get this STAB vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STAB vs SCHDSTAB vs JEPISTAB vs OSTAB vs KOSTAB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.